Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATCell for Long COVID
NCT05669261Phase 1Unknown
- Sponsor
- American CryoStem Corporation
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Mesenchymal Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
01
Overview
Phase 1, randomised, double-blind trial in post-acute sequelae of SARS-CoV-2 infection (PASC) comparing ATCell Treatment Group with Placebo (2 arms). Primary endpoints: Incidence of Serious Adverse Events and Change in Health Status using SF-36 at 4 weeks. Status: unknown.
02
Drugs
astrostem
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT05669261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669261.